Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632
This examiner grants 35% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17426467 | RNA-TARGETING CAS ENZYMES | Non-Final OA | The Regents of the University of California |
| 17262460 | Treatment of Vascular Occlusion by Activation of Notch Signaling | Non-Final OA | The Regents of the University of California |
| 17842715 | CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS | Final Rejection | Genentech, Inc. |
| 17610124 | EXTRACELLULAR MATRIX MATERIAL AND USES THEREOF | Non-Final OA | The Chinese University of Hong Kong |
| 17802577 | PRODUCTION METHOD OF RETINAL PIGMENT EPITHELIAL CELL | Non-Final OA | RIKEN |
| 17798947 | METHOD FOR SUPPRESSING DIFFERENTIATION OF PLURIPOTENT STEM CELLS | Final Rejection | RIKEN |
| 17048289 | INDUCTION OF MYELINATING OLIGODENDROCYTES IN HUMAN CORTICAL SPHEROIDS | Final Rejection | Case Western Reserve University |
| 17738843 | EX VIVO TISSUE EXPLANT AND GRAFT PLATFORM AND USES THEREOF | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17272204 | MEDIUM COMPOSITION FOR SUSPENSION CULTURE OF ADHESIVE CELLS | Final Rejection | NISSAN CHEMICAL CORPORATION |
| 17611241 | HIGH CONCENTRATION CELL PACKAGING AND SHIPPING | Non-Final OA | Rutgers, The State University of New Jersey |
| 18757662 | Renal Progenitor Cells | Non-Final OA | The University of Queensland |
| 17310007 | FIBROBLAST REGENERATIVE CELLS | Non-Final OA | Figene, LLC |
| 17309649 | THERAPEUTIC USES OF GENE EDITED FIBROBLASTS | Non-Final OA | Figene, LLC |
| 17052859 | PAIN-REDUCING EFFECTS OF FIBROBLASTS AND TREATMENT OF PAIN | Final Rejection | Figene, LLC |
| 18028156 | MINI-BRAIN STRUCTURE AND CONSTRUCTION METHOD THEREFOR | Non-Final OA | SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION |
| 17606644 | SYNTHETIC SELF-REPLICATING RNA VECTORS ENCODING CRISPR PROTEINS AND USES THEREOF | Non-Final OA | EMD Millipore Corporation |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 17779275 | METHODS OF REPROGRAMMING A CELL | Final Rejection | MONASH UNIVERSITY |
| 17605714 | TREATMENT OF KIDNEY DISEASE IN SUBJECTS WITH KIDNEY AND/OR URINARY TRACT ANOMALIES | Non-Final OA | ProKidney |
| 17436374 | POROUS CELLULAR SCAFFOLD COMPRISING SERUM-DERIVED PROTEIN, AND PRODUCTION METHOD THEREFOR | Non-Final OA | DANAGREEN CO., LTD. |
| 17610857 | COMPOSITION FOR CULTURING NATURAL KILLER CELLS, AND METHOD USING SAME | Non-Final OA | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17277406 | INSULIN-PRODUCING CELLS | Non-Final OA | Orizuru Therapeutics, Inc. |
| 18195223 | COLD PLASMA TREATMENT MEDIATED TUMOR SPECIFIC T CELL THERAPY | Non-Final OA | Jerome Canady Research Institute for Advanced Biological and Technological Sciences |
| 18246186 | METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO DOPAMINERGIC NERVE CELLS IN MIDBRAIN SUBSTANTIA NIGRA | Non-Final OA | UniXell Biotechnology |
| 17630079 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | Celularity Inc. |
| 17426899 | DISEASE MODEL | Final Rejection | NAGASAKI UNIVERSITY |
| 17781944 | METHOD AND KIT FOR CELL GROWTH | Final Rejection | PRECISION CANCER TECHNOLOGIES INC . |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | Final Rejection | Trallhead Biosystems Inc. |
| 17570266 | Composite 3D Brain Organoids with Optic Structures, Uses Thereof and Culture Medium for Obtaining Them | Final Rejection | NEURONFAB GmbH |
| 17623481 | CELL FOR RESISTING TRANSPLANT REACTION AND METHOD | Non-Final OA | CARsgen Life Sciences Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy